# Abbott India share price today (Abbott India Ltd, NSE: ABBOTINDIA)

> Abbott India share price today: ₹27,120.00 at the NSE close on 4 November 2026, down 5.8% in a year. Abbott India (NSE: ABBOTINDIA) is worth ₹57,630 crore, trades at a P/E of 35.6 and has closed between ₹25,030.00 and ₹30,075.00 over the past 52 weeks. > Abbott India Ltd's earnings have grown faster than its share price. Earnings per share grew +9.7% in a year while the price moved −5.8%. ABBOTINDIA · Pharma - MNC bulk Drugs · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/abbott-india-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: ₹27,120.00 (−5.8% in a year)
- P/E: 35.6× (lower than 88% of the last 11 years)
- Revenue (Jun 2026): ₹1,814 Cr (+4.4% on a year ago)
- Profit (Jun 2026): ₹429 Cr (+17.2% on a year ago)
- Operating margin: 29.0% (+3.0 points on a year ago)
- ROCE: 45%, FY26
- ROIC: 52.2%, against a 12.0% cost of capital: +40.2 points

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Abbott India share price today? Abbott India Ltd's share price was ₹27,120.00 at the close on 4 November 2026. It has been falling for 53 weeks. That is 0.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹25,030 and ₹30,075, and at that close it sat 41% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row. Over the last 11 years the share price moved +458% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Abbott India this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), profit up on a year earlier for 11 quarters in a row (every quarter we can compare) and foreign funds (FIIs) raised their stake for 4 quarters in a row. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹1,814 crore, +4.4% on a year earlier. 2. Profit up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter profit was ₹429 crore, +17.2% on a year earlier. 3. Foreign funds (FIIs) raised their stake for 4 quarters in a row From 0.2% to 0.4% of the company by the September 2026 quarter. ## What are Abbott India's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Abbott India reported revenue of ₹1,814 crore, up 4.4% from ₹1,738 crore a year earlier, and a profit of ₹429 crore, up 17.2% from ₹366 crore. ### Abbott India results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹1,814 crore | ₹1,738 crore | +4.4% |
| Profit | ₹429 crore | ₹366 crore | +17.2% |
| Earnings per share | ₹201.66 | ₹172.18 | +17.1% |
| Operating margin | 29.0% | 26.0% | +3.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Abbott India share price history? Abbott India closed at ₹27,120.00 on 4 November 2026, down 5.8% from ₹28,785.00 a year earlier (7 November 2025) and up 33.6% over five years. Its highest weekly close since March 2016 was ₹34,940.00 on 27 June 2025. ### Abbott India share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹25,635.00 | +5.8% |
| 1 month ago · 1 Oct 2026 | ₹26,840.00 | +1.0% |
| 6 months ago · 8 May 2026 | ₹26,700.00 | +1.6% |
| 1 year ago · 7 Nov 2025 | ₹28,785.00 | −5.8% |
| 3 years ago · 3 Nov 2023 | ₹22,796.15 | +19.0% |
| 5 years ago · 4 Nov 2021 | ₹20,295.05 | +33.6% |
| 10 years ago · 4 Nov 2016 | ₹4,697.30 | +477.4% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹4,856.95 | +458.4% |
| Highest weekly close since March 2016 · 27 Jun 2025 | ₹34,940.00 | −22.4% |
| Lowest weekly close since March 2016 · 26 May 2017 | ₹4,114.25 | +559.2% |
| 52-week high (weekly close) · 28 Nov 2025 | ₹30,075.00 | −9.8% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹25,030.00 | +8.3% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (561 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on Abbott India? 4 Nov 2026: Abbott India closed at ₹27,120.00, up 5.8% on the week and up 1.0% on the month. 24 Jul 2026: ex-date for a dividend + special dividend of ₹656 a share. ### Earlier

- Results for April to June 2026: Revenue up 4.4% and profit up 17.2% on a year earlier. ## What dividend does Abbott India pay? Abbott India paid ₹525 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 1.94% at the ₹27,120.00 close on 4 November 2026. The last was a dividend + special dividend of ₹656 a share, ex-date 24 July 2026. ### Abbott India dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 24 Jul 2026 | ₹656 | Dividend + Special |
| 25 Jul 2025 | ₹475 | Dividend |
| 19 Jul 2024 | ₹410 | Dividend |
| 21 Jul 2023 | ₹325 | Dividend + Special |
| 2 Aug 2022 | ₹275 | Dividend + Special |
| 19 Jul 2021 | ₹275 | Dividend + Special |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

₹131 Special dividends, last 12 months

Yes. Abbott India Ltd paid out 90% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## Which stock lists is Abbott India on? Abbott India is on 4 of our India lists: 52 week high & low, Dividend stocks, Small & mid cap stocks and Pharma stocks. - [52 week high & low 52-week position: Near 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india)
- [Dividend stocks Regular dividend yield (%): 1.94](https://www.sectoralpha.in/dividend-stocks-india)
- [Small & mid cap stocks Size rank in India: 183](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 57629.603276770045](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Abbott India profitable? Abbott India Ltd earned ₹429 Cr of net profit in the Jun 2026 quarter, +17.2% on the same quarter a year earlier. That is the 12th quarter in a row of profit growth. Full-year FY26 profit was ₹1,552 Cr. Over 10 years profit has grown 19.8% a year on average. That is 23.6% of the quarter's revenue. The same quarter a year earlier earned ₹366 Cr. For the full year, FY26 profit was ₹1,552 Cr (+9.8% on the year before). Why profit moved: revenue changed +4.4% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +11.1% and revenue +6.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Abbott India make, and is it growing? Abbott India Ltd reported ₹1,814 Cr of revenue in the Jun 2026 quarter, +4.4% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 10.2% a year on average. The last full year, FY26, came in at ₹6,929 Cr. The last four reported quarters add to ₹7,005 Cr. FY26 revenue was ₹6,929 Cr, +8.1% on the year before. Recent pace: the last four quarters grew +6.3% on average, against 10.2% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +6.3%, against +8.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +11.1%, against +14.2% a year (rolling over). ## How much of every ₹100 of sales does Abbott India keep? Abbott India Ltd's operating margin was 29.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 12.0% and 27.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +3.2 percentage points on the year while gross margin changed +2.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Abbott India's profit turning into cash? Over the last 3 years, 85% of Abbott India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,319 Cr of operating cash against ₹1,552 Cr of profit. After ₹59.0 Cr of spending on assets, ₹1,260 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 85% of profit came in as cash: the cash cycle got 11 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Abbott India's cash go? Abbott India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 3 days in FY26, down from 14 days in FY21. It spent ₹315 Cr on assets over the last 3 years. Customers take 19 days to pay, and stock sits for 94 days on average. At FY26 sales of ₹6,929 Cr, each day of that cycle ties up about ₹19.0 Cr, so roughly ₹57.0 Cr is tied up in the business at any time. FY26: customers took 19 days to pay and stock sat for 94 days, about 3.1 months of sales sitting as stock, for a full cycle of 3 days, shorter than FY21's 14. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 94 days. Customers pay about 19 days after that. Suppliers are paid at 109 days. Together that makes the 3-day cycle. Spending on assets: ₹315 Cr over the last 3 years, against ₹219 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹6.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Abbott India's P/E ratio, and how does it compare with its own history? Abbott India Ltd's P/E is 35.6×, near the low end of its own history: it has been lower only 12% of the time. Its usual P/E (the middle reading) is 46.5×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +9.7% while the price moved −5.8%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +6.0% a year; about +18.0% a year came from earnings growth and about −12.0 percentage points from the multiple (the market paying less); over 10 years the price moved +19.2% a year; about +19.3% a year came from earnings growth and about −0.1 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Abbott India business getting better or worse? Abbott India Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 45.8%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## How much does Abbott India earn on its capital? Abbott India Ltd earned a ROCE of 45% in FY26. That is up from a low of 34% in FY17. Its return on capital used (ROIC) is 40.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 22.4% net margin and 1.07× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 22.4% net margin × 1.07× asset turnover × 1.36× leverage (assets divided by equity) ≈ 32.6% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 52.2% − 12.0% = +40.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 52.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 67.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Abbott India have too much debt? Abbott India Ltd has total debt of ₹172 Cr against shareholder equity of ₹4,774 Cr as of Jun 2026, so its debt is 0.04× its equity, which is very little. Year by year, that ratio went from 0.05 in FY22 to 0.04 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Abbott India shareholding pattern? No group of Abbott India Ltd's owners changed its stake by a full percentage point over the last two years. Promoters moved +0.0 points over the same period, to 75.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +0.2 points over 8 quarters, to 0.4%; Promoters: +0.0 points over 8 quarters, to 75.0%; Domestic institutions: +0.0 points over 8 quarters, to 9.0%. ## How far is Abbott India from balance-sheet trouble? For Abbott India Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Abbott India rank in its industry? 52.1 out of 100, rank 5 of 8 in Pharma - MNC bulk Drugs, with 81% of the evidence available. Abbott India Ltd scores 52.1 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 5. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 18.9 + 15.2 + 7.9 + 10.1 = 52.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Abbott India compared with? Abbott India ranks 5 of 8 Pharma - MNC bulk Drugs companies on the 4-Factor Sector Score, with 52.1 out of 100. 1. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) PGHL · quiet · Most evidence points up · 81% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 12.6% · Profit 19.3% · Operating margin change 0 points · 88% evidence Capital efficiency 16.6/25 · ROCE 83.9% · Operating margin 27% · 100% evidence Valuation 13.1/20 · P/E 28.2× · PEG 1.23 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 6.5% · 1 year -8% · 25% evidence · 1 of 12 weeks ahead Exact sum: 24.1 + 16.6 + 13.1 + 12 = 65.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) GLAXO · losing its lead · Evidence leans up · 96% evidence 59.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 5.8% · Profit 12.4% · Operating margin change 0 points · 88% evidence Capital efficiency 19.6/25 · ROCE 61.4% · Operating margin 31% · 100% evidence Valuation 6.4/20 · P/E 40.1× · PEG 4.12 · 100% evidence Relative strength 15.2/20 · Lead over its industry 2% · Lead over NIFTY 500 4.3% · 1 year -4.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.1 + 19.6 + 6.4 + 15.2 = 59.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 3. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) SANOFICONR · quiet · Evidence leans up · 93% evidence 58.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 22.5% · Profit 28.4% · Operating margin change 3 points · 100% evidence Capital efficiency 21.5/25 · ROCE 89.9% · Operating margin 39% · 100% evidence Valuation 13.5/20 · P/E 28.3× · PEG 1.07 · 65% evidence Relative strength 0.0/20 · Lead over its industry -19.5% · Lead over NIFTY 500 -17.6% · 1 year -28.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.7 + 21.5 + 13.5 + 0 = 58.7 · What this means: Earnings are strong; relative strength in its sector is -19.5% and the one-year return is -28.9%. 4. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) PFIZER · quiet · Evidence leans up · 96% evidence 52.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.8/35 · Revenue 10.6% · Profit -9.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.5/25 · ROCE 24.1% · Operating margin 38% · 100% evidence Valuation 19.6/20 · P/E 21.9× · PEG 0.73 · 100% evidence Relative strength 3.4/20 · Lead over its industry -18.8% · Lead over NIFTY 500 -16.8% · 1 year -29.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.8 + 15.5 + 19.6 + 3.4 = 52.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 5. Abbott India Ltd this page ABBOTINDIA · quiet · Evidence leans up · 81% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.9/35 · Revenue 6.3% · Profit 11.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.2/25 · ROCE 44.8% · Operating margin 29% · 100% evidence Valuation 7.9/20 · P/E 33.7× · PEG 3.6 · 100% evidence Relative strength 10.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.6% · 1 year -11.6% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.9 + 15.2 + 7.9 + 10.1 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) SANOFI · turning · Evidence leans down · 100% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue -5.7% · Profit 2.5% · Operating margin change 5 points · 100% evidence Capital efficiency 15.6/25 · ROCE 57.5% · Operating margin 33% · 100% evidence Valuation 7.4/20 · P/E 20.2× · PEG 3.22 · 100% evidence Relative strength 10.3/20 · Lead over its industry -8.3% · Lead over NIFTY 500 -5.7% · 1 year -33% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.6 + 15.6 + 7.4 + 10.3 = 47.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Novartis India Ltd](https://www.sectoralpha.in/stocks/novartis-india-ltd) NOVARTIND · breaking out · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.2/35 · Revenue 5.4% · Profit -4.9% · Operating margin change 3 points · 88% evidence Capital efficiency 8.1/25 · ROCE 16.3% · Operating margin 34% · 100% evidence Valuation 5.6/20 · P/E 42.7× · PEG 1.96 · 100% evidence Relative strength 16.7/20 · Lead over its industry 40.3% · Lead over NIFTY 500 41.9% · 1 year 95.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.2 + 8.1 + 5.6 + 16.7 = 45.6 · What this means: Relative strength against the index is 41.9%, and revenue and profit growth are weak. 8. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ASTRAZEN · basing · Most evidence points down · 74% evidence 30.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue 31.2% · Profit -7.1% · Operating margin change -8 points · 88% evidence Capital efficiency 8.1/25 · ROCE 29.3% · Operating margin 7% · 100% evidence Valuation 4.1/20 · P/E 91.7× · PEG 3.95 · 65% evidence Relative strength 8.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.4% · 1 year -33.4% · 25% evidence · 0 of 12 weeks ahead Exact sum: 10 + 8.1 + 4.1 + 8 = 30.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - MNC bulk Drugs](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs), all 8 compared on one page. ## Which companies are close to Abbott India in size? Abbott India is the largest of 8 Pharma - MNC bulk Drugs companies on Sector Alpha by market value (scores of 30 October 2026). It is the largest. Just below it: Glaxosmithkline Pharmaceuticals, Pfizer, Astrazeneca Pharma India, Procter & Gamble Health, Sanofi Consumer Healthcare India and Sanofi India. ### Pharma - MNC bulk Drugs companies close in size

1. Abbott India Ltd ₹54,474 crore
2. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) ₹42,255 crore
3. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) ₹16,871 crore
4. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ₹15,911 crore
5. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) ₹9,413 crore
6. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) ₹7,928 crore
7. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) ₹7,379 crore

[All 8 Pharma - MNC bulk Drugs companies, largest first](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs#all-companies)

### Companies close in size in other industries

1. [General Insurance Corporation of India](https://www.sectoralpha.in/stocks/general-insurance-corporation-of-india) ₹54,536 crore · Finance - Non Life Insurance
2. [RBL Bank Ltd](https://www.sectoralpha.in/stocks/rbl-bank-ltd) ₹54,504 crore · Banks - Private
3. Abbott India Ltd ₹54,474 crore
4. [Berger Paints India Ltd](https://www.sectoralpha.in/stocks/berger-paints-india-ltd) ₹54,231 crore · Building Materials - Paints
5. [Altius Telecom Infrastructure Trust](https://www.sectoralpha.in/stocks/altius-telecom-infrastructure-trust) ₹53,025 crore · Infrastructure Investment Trusts

## What else do people ask about Abbott India? ### What is Abbott India's share price today? Abbott India Ltd's share price is ₹27,120.00, −5.8% over the past year. The whole company is worth ₹57,630 Cr on the market. In the last 52 weeks it traded between ₹25,030 to ₹30,075; today it is 41% of the way up from the low, 0.4% above its 200-day average (as of 4 November 2026). ### What were Abbott India's latest quarterly results? Abbott India Ltd reported revenue of ₹1,814 Cr and net profit of ₹429 Cr for the Jun 2026 quarter. Revenue rose 4.4% and profit rose 17.2% compared with a year earlier. Earnings per share were ₹201.66. The operating margin was 29.0%, 3.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Abbott India's market cap? Abbott India Ltd's market capitalisation is ₹57,630 Cr at a share price of ₹27,120.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Abbott India performing? Abbott India Ltd's share price has been falling for 53 weeks. In its latest quarter, revenue rose 4.4% and profit rose 17.2% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 1 week running (as of 4 November 2026). ### Will Abbott India's share price go up? This page does not forecast Abbott India Ltd's share price. What it shows instead: the share price is ₹27,120.00, and it has been falling for 53 weeks. Its P/E of 35.6× is higher than 12% of its own last 11 years (as of 4 November 2026). ### Who owns Abbott India? Promoters own 75.0% of Abbott India Ltd, foreign institutions 0.4%, domestic institutions 9.0% and the public 15.6% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 4 November 2026). ### Does Abbott India have too much debt? No, Abbott India Ltd has little debt: its debt is 0.04× its equity, and its operating profit is 76 times its interest bill. FY26 borrowings were ₹172 Cr against equity of ₹4,774 Cr. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### Where is Abbott India in its business cycle? Abbott India Ltd's FY26 operating margin was 27.0%, against a 13-year range of 12.0% to 27.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 29.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Abbott India story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Abbott India a stock worth studying right now? What the numbers show: Abbott India Ltd's earnings have grown faster than its share price. Earnings per share grew +9.7% in a year while the price moved −5.8%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india
- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india
- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.